Format

Send to

Choose Destination
J Med Chem. 2016 Aug 25;59(16):7525-43. doi: 10.1021/acs.jmedchem.6b00516. Epub 2016 Aug 10.

Peripherally Selective Cannabinoid 1 Receptor (CB1R) Agonists for the Treatment of Neuropathic Pain.

Author information

1
Center for Drug Discovery, Research Triangle Institute , Research Triangle Park, North Carolina 27709, United States.
2
Division of Oral Biology & Medicine, School of Dentistry, University of California , 10833 Le Conte Avenue, 63-078 CHS, Los Angeles, California 090095-1668, United States.

Abstract

Alleviation of neuropathic pain by cannabinoids is limited by their central nervous system (CNS) side effects. Indole and indene compounds were engineered for high hCB1R affinity, peripheral selectivity, metabolic stability, and in vivo efficacy. An epithelial cell line assay identified candidates with <1% blood-brain barrier penetration for testing in a rat neuropathy induced by unilateral sciatic nerve entrapment (SNE). The SNE-induced mechanical allodynia was reversibly suppressed, partially or completely, after intraperitoneal or oral administration of several indenes. At doses that relieve neuropathy symptoms, the indenes completely lacked, while the brain-permeant CB1R agonist HU-210 (1) exhibited strong CNS side effects, in catalepsy, hypothermia, and motor incoordination assays. Pharmacokinetic findings of ∼0.001 cerebrospinal fluid:plasma ratio further supported limited CNS penetration. Pretreatment with selective CB1R or CB2R blockers suggested mainly CB1R contribution to an indene's antiallodynic effects. Therefore, this class of CB1R agonists holds promise as a viable treatment for neuropathic pain.

PMID:
27482723
PMCID:
PMC5474949
DOI:
10.1021/acs.jmedchem.6b00516
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for American Chemical Society Icon for PubMed Central
Loading ...
Support Center